

## Blood pressure changes after intravitreal bevacizumab in patients grouped by ocular pathology

Y-R Chung, K Lee, E-H Cho and HM Lew

*Eye* (2010) 24, 1736; doi:10.1038/eye.2010.143

**Correction to:** *Eye* (2010) 24, 1320–1324; doi:10.1038/eye.2010.22; published online 9 April 2010

The marketing authorization holder for bevacizumab (Avastin) was published

incorrectly as Novartis in the above-referenced paper. The correct marketing authorization holder is Roche.

The authors would like to apologize for this error.